Nice job Alex.
The lack of data about ezetimibe highlights an aspect of the drug approval system that even sophisticated patients may not understand. Many medicines are approved on the basis of what scientists call surrogate endpoints, like proof that they lower cholesterol, rather than because they have been shown to reduce the risk of death or disease.
“The only place people should be taking (ezetimibe) is in a clinical trial,”
Dr. Allen J. Taylor of the Walter Reed Army Medical Center
More
The lack of data about ezetimibe highlights an aspect of the drug approval system that even sophisticated patients may not understand. Many medicines are approved on the basis of what scientists call surrogate endpoints, like proof that they lower cholesterol, rather than because they have been shown to reduce the risk of death or disease.
“The only place people should be taking (ezetimibe) is in a clinical trial,”
Dr. Allen J. Taylor of the Walter Reed Army Medical Center
More
No comments:
Post a Comment